Drug intelligence / Profile preview

TrichoGene MinoxyBoost

Development stage: Unknown
Lead developer: Trichogene
Modality: Small Molecules
Administration: Topical

Overview

TrichoGene MinoxyBoost is a topical retinoid gel containing 0.1% tretinoin, developed by Trichogene. It is specifically indicated for individuals with androgenetic alopecia who do not respond to minoxidil treatment. The drug functions by upregulating the activity of the scalp sulfotransferase enzyme (SULT1A1). This enzyme is responsible for converting minoxidil into its active metabolite, minoxidil sulfate. By increasing SULT1A1 levels, MinoxyBoost aims to convert minoxidil non-responders into responders, thereby improving hair regrowth outcomes.

Brand names: TrichoGene MinoxyBoost
Other names: Tretinoin 0.1%Sulfotransferase enzyme booster

Targets

RARA (Retinoic acid receptor alpha)SULT1A1 (Sulfotransferase 1A1)

Beyond the preview

Go deeper on TrichoGene MinoxyBoost.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TrichoGene MinoxyBoost.

Explore the full profile